Press release BoxID: 128116 (Evolva Holding SA)
  • Evolva Holding SA
  • Duggingerstraße 23
  • 4153 Reinach
  • Contact person
  • Khalid Islam
  • +41 (61) 4179660

Arpida's Extensive Presence at ICAAC Well-Received

(PresseBox) (Reinach, ) Arpida Ltd (SWX: ARPN) had a significant presence at this year’s Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a premier meeting for clinicians, researchers and scientists in the field of infectious diseases.

Arpida, for the first time, had a booth which encountered significant interest among the conference attendees. Moreover, Arpida presented a total of 32 posters at ICAAC, nineteen of which were on the latestage investigational antibiotic iclaprim. One of the posters discussed detailed microbiological efficacy data from ASSIST-1, the first of two pivotal Phase III trials in complicated Skin and Skin Structure Infections. In this study iclaprim showed a high microbiological eradication rate against MRSA which was comparable to that of linezolid (84.7% versus 85.3%). Another key highlight was the poster discussing the results of a large study, investigating iclaprim’s efficacy against a panel of Staphylococcus aureus isolates from the USA and Europe. With a total of 4,516 isolates, this was one of the largest surveillance studies ever done in this area and confirmed iclaprim’s potent activity. Apart from the posters on iclaprim, Arpida presented thirteen posters on two additional compounds: AR-709 and AR-2474.

Arpida also supported a wellattended symposium at ICAAC with the title "Treatment of Methicillinresistant Staphylococcus aureus and Other Resistant Infections: An Expert Debate". In this meeting distinguished speakers such as John G. Bartlett, MD, Louis B. Rice, MD, Dennis L. Stevens, PhD, MD, Gregory J. Moran, MD, FACEP and Robert C. Moellering, Jr., MD, MACP discussed the latest trends in their field.

Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "I am delighted about the large number of people showing an interest in our compounds as well as the very positive feedback that we encountered among practicing physicians and key opinion leaders. I feel this conference and the material that we’ve presented have significantly raised the awareness of iclaprim in key audiences. We very much look forward to building on this strength at the upcoming annual meeting of the Infectious Diseases Society of America (IDSA) next week in San Diego."

Evolva Holding SA

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance.

Arpida’s leading product candidate is intravenous iclaprim, a broadspectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillinresistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In July 2007, Arpida reported the completion of the Phase III programme in complicated skin and skin structure infections. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospitalacquired pneumonia (HAP), ventilatorassociated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida’s fourth most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "firstinman" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.